Accessibility Menu
Aptevo Therapeutics Stock Quote

Aptevo Therapeutics (NASDAQ: APVO)

$1.51
(-3.8%)
-0.06
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.51
Daily Change
(-3.8%) $0.06
Day's Range
$1.48 - $1.56
Previous Close
$1.51
Open
$1.56
Beta
1.33
Volume
1,059,020
Average Volume
5,470,466
Market Cap
21.7M
Market Cap / Employee
$1.57M
52wk Range
$1.32 - $298
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$540.69
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Aptevo Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
APVO-99.11%-100%-90.76%-100%
S&P+15.06%+95.03%+14.29%+210%

Aptevo Therapeutics Company Info

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.05M46.2%
Market Cap$9.83M4671.3%
Market Cap / Employee$0.23M0.0%
Employees425.0%
Net Income-$6.20M-5.5%
EBITDA-$6.18M-4.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$9.41M16.7%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$4.21M-16.2%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-157.31%-42.1%
Return On Invested Capital-109.88%5.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$7.09M-15.3%
Operating Free Cash Flow-$7.09M-15.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.691.32-1.15-0.15-546.75%
Price to Tangible Book Value121.658.997.12-0.15-100.60%
Enterprise Value to EBITDA0.20-0.35-0.620.4844.26%
Return on Equity-251.0%-284.3%-1023.9%-437.3%79.42%
Total Debt$4.83M$4.63M$4.42M$4.21M-16.24%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.